TORONTO, ON / ACCESSWIRE / June 10, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX Venture: TLT) (TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its next generation therapeutic laser, the TLC-2000, has recently received safety approval from the Canadian Standards Association ("CSA").
CSA conducted an in-depth review of the Company's technical testing results and approved the product in accordance with the latest international medical standards, including Canadian and US standards. The CSA safety approval paves the way for formal Health Canada approval anticipated in early July 2015.
The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology "senses" the exact location of injured tissue in a body and then automatically adjusts for a patient's physical characteristics to deliver an optimized dose of laser light energy to heal the injury faster and more effectively than any other laser product on the market.
Roger Dumoulin-White, President and CEO of Theralase stated that, "In order to develop cutting edge technology that is superior to any existing technology on the market and in the process creating a new industry standard takes: vision, knowledge, perseverance, capital and luck. Thankfully, Theralase was blessed to have all five in the creation of the next generation TLC-2000 therapeutic laser system over the last few years. I join my entire organization into welcoming the debut of the next generation cold laser therapy product to Canadian healthcare practitioners within the next 30 days."
